Britain and America have forged a landmark commercial pact that will ensure zero duties on UK medicine exports going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to raise funding on drugs through the public health system. This move ensures that tariffs on these crucial exports will stay at nothing for a timeframe of the next three years.
This deal is in response to previous warnings to dramatically increase tariffs on branded pharmaceutical products, with increases floated up to 100%.
"This agreement with the Britain reinforces the international landscape for cutting-edge drugs and establishes much-needed balance to American-British drug exports," a release declared.
Economic Importance
Drugs represent one of the UK's biggest exports to the US, which is clearly the largest market for leading companies like GSK and AstraZeneca.
Export figures show that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This amount represented 17.4% of British export trade in that span.
"This deal secures jobs, increases investment and facilitates the UK to emerge as a international leader for life sciences," a minister commented.
Detailed British Pledges
The deal involves several specific changes from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be restricted at fifteen percent. In the past, rebates exceeded twenty percent.
Recent Tensions
This agreement takes place against a long-running dispute between the sector and the ministers over drug pricing and NHS adoption.
The disagreement were intensified by arguments that US consumers were paying significantly more for the equivalent treatments than patients in the other developed nations.
In recent months, several major drug company projects in the UK have been halted or scrapped, while substantial investments have been pledged toward US facilities.
A senior figure publicly accepted that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its resources over the past decade.
